Soekhai V, De Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37(2):201–26. https://doi.org/10.1007/s40273-018-0734-2.
Bridges JFP, Kinter ET, Kidane L, Heinzen RR, McCormick C. Things are looking up since we started listening to patients. Patient Patient-Cent Outcomes Res. 2008;1(4):273–82. https://doi.org/10.2165/1312067-200801040-00009.
Brett Hauber A, Fairchild AO, Reed JF. Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature. Appl Health Econ Health Policy. 2013;11(4):319–29. https://doi.org/10.1007/s40258-013-0028-y.
Marsh K, Van Til JA, Molsen-David E, Juhnke C, Hawken N, Oehrlein EM, et al. Health preference research in Europe: a review of its use in marketing authorization, reimbursement, and pricing decisions—report of the ISPOR stated preference research special interest group. Value Health. 2020;23(7):831–41. https://doi.org/10.1016/j.jval.2019.11.009.
Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G, et al. Partnering with patients in the development and lifecycle of medicines. Ther Innov Regul Sci. 2015;49(6):929–39. https://doi.org/10.1177/2168479015580384.
Mavris M, Furia Helms A, Bere N. Engaging patients in medicines regulation: a tale of two agencies. Nat Rev Drug Discovery. 2019;18(12):885–6. https://doi.org/10.1038/d41573-019-00164-y.
Haerry D, Landgraf C, Warner K, Hunter A, Klingmann I, May M, et al. EUPATI and patients in medicines research and development: guidance for patient involvement in regulatory processes. Front Med. 2018;5:230. https://doi.org/10.3389/fmed.2018.00230.
Anderson M, Kimberly MK. On the path to a science of patient input. Sci Transl Med. 2016;8(336):336ps11-ps11. https://doi.org/10.1126/scitranslmed.aaf6730.
European Medicines Agency. ICH reflection paper on proposed ICH guideline work to advance patient focused drug Development. EMA/CHMP/ICH/415588/2020. Committee for Medicinal Products for Human Use, European Medicines Agency; 2020.
European Medicines Agency. The patient's voice in the evaluation of medicines: how patients can contribute to assessment of benefit and risk. EMA/607864/2013. Stakeholders and Communication Division, European Medicines Agency; 2013.
US FDA. Patient-focused drug development: collecting comprehensive and representative input; guidance for industry, food and drug administration staff, and other stakeholders. Silver Spring: Center for Drug Evaluation and Research, US FDA; 2020.
US FDA. Patient Preference Information – Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Silver Spring: US FDA; 2016.
Ho M, Saha A, McCleary KK, Levitan B, Christopher S, Zandlo K, et al. A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies. Value Health. 2016;19(6):746–50. https://doi.org/10.1016/j.jval.2016.02.019.
Reynolds RF, Kurz X, De Groot MCH, Schlienger RG, Grimaldi-Bensouda L, Tcherny-Lessenot S, et al. The IMI PROTECT project: purpose, organizational structure, and procedures. Pharmacoepidemiol Drug Saf. 2016;25(Suppl 1):5–10. https://doi.org/10.1002/pds.3933.
Medical Device Innovation Consortium (MDIC). Patient centered benefit‐risk project report: a framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of new medical technology. Medical Device Innovation Consortium; 2015.
Postmus D, Richard S, Bere N, Van Valkenhoef G, Galinsky J, Low E, et al. Individual trade-offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma. Oncologist. 2018;23(1):44–51. https://doi.org/10.1634/theoncologist.2017-0257.
Mühlbacher AC, Juhnke C, Beyer AR, Garner S. Patient-focused benefit-risk analysis to inform regulatory decisions: the European union perspective. Value Health. 2016;19(6):734–40. https://doi.org/10.1016/j.jval.2016.04.006.
Johnson FR, Zhou M. Patient preferences in regulatory benefit-risk assessments: a US perspective. Value Health. 2016;19(6):741–5. https://doi.org/10.1016/j.jval.2016.04.008.
Levitan B, Hauber AB, Damiano MG, Jaffe R, Christopher S. The ball is in your court: agenda for research to advance the science of patient preferences in the regulatory review of medical devices in the United States. Patient Patient-Cent Outcomes Res. 2017;10(5):531–6. https://doi.org/10.1007/s40271-017-0272-6.
De Bekker-Grob EW, Berlin C, Levitan B, Raza K, Christoforidi K, Cleemput I, et al. Giving patients’ preferences a voice in medical treatment life cycle: the PREFER public-private project. Patient Patient-Cent Outcomes Res. 2017;10(3):263–6. https://doi.org/10.1007/s40271-017-0222-3.
Russo S, Jongerius C, Faccio F, Pizzoli SFM, Pinto CA, Veldwijk J, et al. Understanding patients’ preferences: a systematic review of psychological instruments used in patients’ preference and decision studies. Value Health. 2019;22(4):491–501. https://doi.org/10.1016/j.jval.2018.12.007.
Van Overbeeke E, Whichello C, Janssens R, Veldwijk J, Cleemput I, Simoens S, et al. Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review. Drug Discov Today. 2019;24(1):57–68. https://doi.org/10.1016/j.drudis.2018.09.015.
Janssens R, Huys I, Van Overbeeke E, Whichello C, Harding S, Kübler J, et al. Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review. BMC Med Inform Decis Mak. 2019;19(1):189. https://doi.org/10.1186/s12911-019-0875-z.
Soekhai V, Whichello C, Levitan B, Veldwijk J, Pinto CA, Donkers B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discovery Today. 2019;24(7):1324–31. https://doi.org/10.1016/j.drudis.2019.05.001.
Whichello C, Bywall KS, Mauer J, Stephen W, Cleemput I, Pinto CA, et al. An overview of critical decision-points in the medical product lifecycle: where to include patient preference information in the decision-making process? Health Policy. 2020;124(12):1325–32. https://doi.org/10.1016/j.healthpol.2020.07.007.
Van Overbeeke E, Janssens R, Whichello C, Schölin Bywall K, Sharpe J, Nikolenko N, et al. Design, conduct, and use of patient preference studies in the medical product life cycle: a multi-method study. Front Pharmacol. 2019;10:1395. https://doi.org/10.3389/fphar.2019.01395.
Janssens R, Russo S, Van Overbeeke E, Whichello C, Harding S, Kübler J, et al. Patient Preferences in the medical product life cycle: what do stakeholders think? Semi-structured qualitative interviews in Europe and the USA. Patient Patient-Cent Outcomes Res. 2019;12(5):513–26. https://doi.org/10.1007/s40271-019-00367-w.
Whichello C, Levitan B, Juhaeri J, Patadia V, Disantostefano R, Pinto CA, et al. Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison. BMC Med Inform Decis Mak. 2020;20(1):114. https://doi.org/10.1186/s12911-020-01142-w.
Van Overbeeke E, Forrester V, Simoens S, Huys I. Use of patient preferences in health technology assessment: perspectives of Canadian, Belgian and German HTA representatives. Patient Patient-Cent Outcomes Res. 2021;14(1):119–28. https://doi.org/10.1007/s40271-020-00449-0.